BRM424 Ophthalmic Solution - Dose2
Phase 2Small molecule
BRM424 Ophthalmic Solution - Dose2 is one of 24 small molecule programs targeting Keratitis. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
23
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
55 competitors in Keratitis
#DrugCompanyPhaseTrials
1Neoral
NovartisApproved
Avelox
BayerApproved
Levaquin
WWim Janssens
Approved
Rayos
RRoxane Laboratories
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Decadron
AAspen Global Incorporated
Approved
Acthar
MMallinckrodt
Approved
OXERVATE
DDompé Farmaceutici S.p.A
Approved
Cenegermin
DDompé Farmaceutici S.p.A
Approved
Oxervate
DDompé Farmaceutici S.p.A
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- BBRIM Biotechnology Inc.